ZENAS BIOPHARMA INC (ZBIO) Stock Price, Quote, News and Overview
NASDAQ:ZBIO - Nasdaq - US98937L1052 - Common Stock - Currency: USD
ZBIO Quote, Performance and Key Statistics
7.83
+0.02 (+0.26%)
The current stock price of ZBIO is 7.83 USD. In the past month the price decreased by -6.56%.
ZBIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ZBIO
Company Profile
Zenas Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2024-09-13. Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The company is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
Company Info
ZENAS BIOPHARMA INC
1000 Winter St, Suite 1200
Waltham MASSACHUSETTS US
Employees: 115
Company Website: https://zenasbio.com/
Phone: 18572712954
ZENAS BIOPHARMA INC / ZBIO FAQ
What is the stock price of ZENAS BIOPHARMA INC today?
The current stock price of ZBIO is 7.83 USD. The price increased by 0.26% in the last trading session.
What is the ticker symbol for ZENAS BIOPHARMA INC stock?
The exchange symbol of ZENAS BIOPHARMA INC is ZBIO and it is listed on the Nasdaq exchange.
On which exchange is ZBIO stock listed?
ZBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZENAS BIOPHARMA INC stock?
11 analysts have analysed ZBIO and the average price target is 32.47 USD. This implies a price increase of 314.69% is expected in the next year compared to the current price of 7.83. Check the ZENAS BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZENAS BIOPHARMA INC worth?
ZENAS BIOPHARMA INC (ZBIO) has a market capitalization of 327.22M USD. This makes ZBIO a Small Cap stock.
How many employees does ZENAS BIOPHARMA INC have?
ZENAS BIOPHARMA INC (ZBIO) currently has 115 employees.
What are the support and resistance levels for ZENAS BIOPHARMA INC (ZBIO) stock?
ZENAS BIOPHARMA INC (ZBIO) has a resistance level at 7.84. Check the full technical report for a detailed analysis of ZBIO support and resistance levels.
Is ZENAS BIOPHARMA INC (ZBIO) expected to grow?
The Revenue of ZENAS BIOPHARMA INC (ZBIO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ZBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ZENAS BIOPHARMA INC (ZBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZBIO, evaluating the profitability, health, valuation and growth aspects
- ZENAS BIOPHARMA INC (ZBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZENAS BIOPHARMA INC (ZBIO) Sales and EPS estimates to see what analysts future expectations are.
- ZENAS BIOPHARMA INC (ZBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZENAS BIOPHARMA INC (ZBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZENAS BIOPHARMA INC (ZBIO) Stock Chart to make your own analysis
- ZENAS BIOPHARMA INC (ZBIO) Latest news and press-releases to stay up to date.
Does ZENAS BIOPHARMA INC (ZBIO) stock pay dividends?
ZBIO does not pay a dividend.
What is the Price/Earnings (PE) ratio of ZENAS BIOPHARMA INC (ZBIO)?
ZENAS BIOPHARMA INC (ZBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.19).
What is the Short Interest ratio of ZENAS BIOPHARMA INC (ZBIO) stock?
The outstanding short interest for ZENAS BIOPHARMA INC (ZBIO) is 10.89% of its float. Check the ownership tab for more information on the ZBIO short interest.
ZBIO Technical Analysis
ZBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZBIO. While ZBIO has a great health rating, there are worries on its profitability.
ZBIO Financial Highlights
Over the last trailing twelve months ZBIO reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS decreased by -299.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.97% | ||
| ROE | -35.88% | ||
| Debt/Equity | 0 |
ZBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to ZBIO. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -703.1% and a revenue growth -100% for ZBIO